The outcome of patients with EGFR mutated lung cancer with bone metastases have been evaluated in six published papers in which the SRE frequency was 0% in only one paper (22), while ranged between 20 and 51% in the remaining five papers (13–17) (Table 4). Here, EGFR is linked to lung carcinoma.